FDA approves Amgen drug for lung cancer with specific mutation

Published by

By Deena Beasley (Reuters) -The U.S. Food and Drug Administration on Friday approved an Amgen Inc drug for lung cancer patients with a specific mutation in a gene known as KRAS whose disease has worsened after treatment with chemotherapy or other medicines. The drug, sotorasib, which will be sold under the brand name Lumakras, shrank tumors with the KRAS mutation in around 36% of patients in clinical trials. The medication is designed to target a gene mutation known as KRAS G12C that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer. Amgen estimate…

Read More

Share this Story
Load More Related Articles
Load More In US News

Facebook Comments

Check Also

Sunshine, perfume and other things you need to protect jewellery from

Published by DPA If you want to extend ...